Hook & thesis
TG Therapeutics just cleared an important milestone: Phase 1 data for subcutaneous (SC) BRIUMVI that materially lowers the clinical and commercial uncertainty around a more convenient dosing route. That matters because the market for multiple sclerosis (MS) therapies prizes efficacy plus ease-of-use; a well-tolerated SC formulation can accelerate uptake, broaden prescriber adoption, and improve adherence - all of which translate into revenue upside beyond IV-only sales.
We view this readout as a de-risking event that supports a tactical long trade. The company already shows commercial traction - BRIUMVI U.S. net sales were $119.7 million in Q1 2025 and management raised full-year guidance to $585 million - and the stock trades near $41.97, roughly 6% below its 52-week high of $44.65. With solid underlying fundamentals (EPS $3.02, P/E ~13.3, market cap ~$6.42 billion) and a crowded short base, this is an asymmetric setup: upside on continued commercial execution and regulatory progress, downside limited by defined stops and technical support.
Business overview and why investors should care
TG Therapeutics is a clinical-stage biopharma focused on B-cell targeted therapies for oncology and autoimmune disease, with BRIUMVI (an anti-CD20 therapy) as the commercial anchor in multiple sclerosis. The company has demonstrated rapid commercial growth: Q1 2025 U.S. net sales of BRIUMVI were $119.7 million and management raised full-year BRIUMVI revenue guidance to $585 million following a 91% increase in Q2 revenue year-over-year.
Why the market should care about the SC formulation: conversion from an IV infusion to a subcutaneous injection typically lowers barriers for outpatient use, reduces administration costs, shortens clinic visits, and improves patient convenience. For BRIUMVI this could broaden prescriber preference versus IV competitors and increase market share in a growing MS category. Put simply: SC BRIUMVI is not just a clinical win; it is a commercial lever.
Supporting numbers and financial context
- Price and valuation snapshot: current price $41.97, market cap roughly $6.42 billion, P/E ~13.3, price-to-sales ~8.77 and EV/EBITDA ~43.1.
- Profitability and cash flow: last reported EPS is $3.02. Free cash flow is negative (-$14.19 million), while enterprise value is approximately $6.44 billion.
- Operational metrics: shares outstanding ~153.08 million, float ~142.12 million; short interest recently ~28.1 million shares (about 19.8% of float) with days-to-cover in the neighborhood of 10 trading days on the latest reported figures.
- Technical context: 50-day SMA is $36.86, 10-day SMA $39.00, RSI at 63.24 (bullish-leaning), and the stock trades ~6% below its 52-week high of $44.65 and well above its 52-week low of $25.28.
Valuation framing
At a market cap near $6.42 billion and trailing P/E of ~13x, TG Therapeutics sits in the sweet spot between growth biotech premiums and established pharma multiples. The price-to-sales ratio (~8.8) looks rich if you assess valuation purely on trailing revenues, but context matters: management raised full-year BRIUMVI revenue guidance to $585 million in 2025, and commercial momentum combined with a successful SC rollout could expand revenue meaningfully over the next 12-24 months. The EV/EBITDA of ~43x is elevated, but the company’s ROE (~79%) and ROA (~30%) point to efficient returns on capital — evidence that earnings are supporting the current multiple.
In short, valuation is not cheap in absolute terms, but the multiple can be supported by continued top-line growth and multiple expansion as clinical risk diminishes and the market gains confidence in broader uptake.
Catalysts (what to watch)
- Regulatory and label expansion path for SC BRIUMVI - positive Phase 1 data should accelerate conversations with regulators and could lead to a path-for-approval or label supplement that shortens time to market for the SC formulation.
- Commercial execution / sales cadence - quarterly sales prints that match or exceed guidance (management guiding $585M for 2025) will be the clearest validation of adoption.
- Payer uptake and formulary wins - expanded coverage and competitive positioning versus IV agents will matter for sustained growth.
- Conferences & investor events - management presentations (e.g., upcoming industry summits) where new data or rollout plans are shared can move the stock.
- Short-pressure dynamic - with almost 20% of the float shorted, any sustained upside on good news could trigger squeezes that amplify moves higher.
Trade plan (actionable)
Thesis: Buy the stock to play the de-risking from positive Phase 1 SC BRIUMVI data, continued BRIUMVI sales acceleration, and a compressed path to label expansion. This is a measured long with a clear stop and a time-bound target.
| Action | Price |
|---|---|
| Entry (market or limit) | $41.97 |
| Stop loss | $36.00 |
| Target | $51.00 |
Horizon: long term (180 trading days). Why this duration? The trade leans on commercial uptake and regulatory progress that can take several quarters to reflect in sales and investor sentiment. A 180-trading-day horizon lets market digestion, payer decisions, and rollout execution play out while maintaining discipline through a defined stop.
Position sizing & risk: limit exposure to a portion of your portfolio consistent with biotech risk (we generally recommend sizing such a trade so that the distance to stop represents no more than 1-2% of portfolio value). The stop at $36 is set below the 50-day SMA (~$36.86) and mental support levels; a break below $36 would indicate the thesis is under stress (slowing adoption, disappointing secondary data, or market-wide risk-off), so exit and reassess rather than add to a failing position.
Risks and counterarguments
- Clinical risk still exists beyond Phase 1 - positive Phase 1 results are encouraging but do not guarantee Phase 2/3 success or regulatory approval for a subcutaneous formulation. Late-stage surprises on safety or efficacy would reverse the de-risking narrative.
- Commercial uptake may be slower than modeled - even with an SC option, prescribers and payers can be conservative. If payers restrict access or patients/physicians prefer established therapies, revenue upside will be muted.
- Valuation vulnerability - the stock trades at strong multiples on sales and earnings; any miss in quarterly revenue or guidance could cause outsized multiple compression.
- Leverage and free cash flow - free cash flow was negative recently, and debt-to-equity is ~1.28, which increases refinancing and operational risk if sales growth stalls or costs rise.
- Short-squeeze volatility cuts both ways - a large short position (~19.8% of float) can amplify moves but also introduce sharp reversals if short sellers press during earnings or negative headlines.
Counterargument: Much of the positive is already priced in. The stock sits close to its 52-week high, and technical indicators show bullish pull but MACD has recently signaled bearish momentum. If market participants have already baked in SC success and commercial upside, upside from here could be limited and the risk/reward compressed. That makes strict stops and conservative sizing essential.
Conclusion and what would change my mind
Conclusion: Positive Phase 1 results for subcutaneous BRIUMVI are a meaningful de-risk for TG Therapeutics. Combined with strong commercial traction (Q1 2025 BRIUMVI sales $119.7 million and a raised 2025 guidance to $585 million), attractive EPS ($3.02) and a reasonable P/E (~13x), the setup warrants a disciplined long position with a long-term (180 trading days) horizon. Entry at $41.97, stop at $36.00, and target $51.00 capture upside from multiple expansion and continued sales growth while limiting downside through a clearly defined stop.
What would change my mind: I would become neutral-to-bearish if (1) Phase 2/3 safety signals or efficacy shortfalls emerge for SC BRIUMVI, (2) quarterly revenue prints miss the raised guidance materially, (3) payers impose restrictive coverage limiting uptake, or (4) the company reports sustained negative free cash flow that forces dilutive financing or slows commercialization. Conversely, accelerating sales above guidance, a clear regulatory path to SC approval, or visible payer/formulary wins would justify adding to the position or raising the target.
Trade summary: Buy TGTX at $41.97, stop $36.00, target $51.00, hold for up to 180 trading days. Keep position size controlled, monitor quarterly sales and regulatory milestones, and respect the stop.
Key points
- Phase 1 SC BRIUMVI results materially reduce clinical/commercial risk and justify a long position.
- Commercial traction is real: Q1 2025 sales $119.7M and full-year guidance of $585M.
- Valuation is supported by EPS of $3.02 and a P/E of ~13x but vulnerable to misses.
- Short interest (~28.1M shares, ~19.8% of float) can amplify moves; manage position size and stop rigorously.